EUVIMEDEUVIMED entdecken
Open Access

Liraglutide versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)

Hiroki Yokoyama, Koichi Hirao, Kohei Yamaguchi, Mariko Oishi, Gendai Lee, Noriharu Yagi, Hiroshi Takamura, Atsunori Kashiwagi

Japanese Clinical Medicine · 2014

DOI: 10.4137/jcm.s16585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Clinical Medicine, 2014. Verfasst von Hiroki Yokoyama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiyugaoka Medical Clinic, Internal Medicine, Obihiro, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Liraglutide (glucagon-like peptide-1 [GLP-1] receptor agonist) and sitagliptin (dipeptidyl peptidase-4 inhibitor) are approved in Japan for treating type 2 diabetes mellitus (T2DM). We compared the efficacy and safety of adding liraglutide or sitagliptin to a sulfonylurea in Japanese T2DM patients.

Methods

Patients aged 18 to

Schlagwörter

Stichwörter der Autor:innen

C peptideRCTType 2 diabetesliraglutidesitagliptinsulfonylureaβ Cell function

Autor:innen und Institutionen

  • Jiyugaoka Medical Clinic, Internal Medicine, Obihiro, Japan.
  • HEC Science Clinic, Yokohama, Japan.
  • Kaiseikai Tsutsumi Hospital, Hitoyoshi, Japan.
  • Oishi Clinic, Kyoto, Japan.
  • Lee Medical Clinic, Kitakyushu, Japan.
  • Yagi Medical Clinic, Naha, Japan.

Zitieren

APA

Yokoyama, H., Hirao, K., Yamaguchi, K., Oishi, M., Lee, G., Yagi, N., Takamura, H., & Kashiwagi, A. (2014). Liraglutide versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). Japanese Clinical Medicine. https://doi.org/10.4137/jcm.s16585

Vancouver

Yokoyama H, Hirao K, Yamaguchi K, Oishi M, Lee G, Yagi N, et al. Liraglutide versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). Japanese Clinical Medicine. 2014. doi:10.4137/jcm.s16585

BibTeX
@article{Yokoyama2014,
  author = {Yokoyama, Hiroki and Hirao, Koichi and Yamaguchi, Kohei and Oishi, Mariko and Lee, Gendai and Yagi, Noriharu and Takamura, Hiroshi and Kashiwagi, Atsunori},
  title = {Liraglutide versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)},
  journal = {Japanese Clinical Medicine},
  year = {2014},
  doi = {10.4137/jcm.s16585}
}
Kostenlos starten →